Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718921 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
A Phase 1 study of Atopic Dermatitis and Psoriasis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT05718921 is a Phase 1 study of Atopic Dermatitis and Psoriasis that has completed, run by Hangzhou Yirui Pharmaceutical Technology Co.. The registered enrollment target is 54 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05718921, a Phase 1 study of Atopic Dermatitis and Psoriasis, has completed, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
Conditions Studied
Interventions
- DRUG YR001 Dose A on low body surface area
- DRUG YR001 Dose A on middle body surface area
- DRUG YR001 Dose A on high body surface area
- DRUG YR001 Dose B on low body surface area
- DRUG YR001 Dose B on middle body surface area
Study Locations (1)
California
- California Dermatology & Clinical Research Institute - Encinitas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-04-08 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05718921
The ClinicalTrials.gov registry entry for NCT05718921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (91% lower). The listed sponsor is Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 5 interventions - of which YR001 Dose A on low body surface area is the first listed.
NCT05718921 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05718921 about?
NCT05718921 is a clinical study titled "A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers". This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
What is the current status of trial NCT05718921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-04-08. Estimated completion is 2023-12-14.
What conditions does trial NCT05718921 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis.
What interventions are being tested in trial NCT05718921?
The interventions under investigation include: YR001 Dose A on low body surface area (DRUG), YR001 Dose A on middle body surface area (DRUG), YR001 Dose A on high body surface area (DRUG), YR001 Dose B on low body surface area (DRUG), YR001 Dose B on middle body surface area (DRUG).
Who is sponsoring clinical trial NCT05718921?
This trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718921 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.